In conclusion, HER2/ErbB3 signaling may be impactful in cisplatin-resistant BlCa, but both cisplatin-sensitive and -resistant BlCa positive for HRG1 may be susceptible to ErbB3 inhibitors like seribantumab if they express high HRG1 levels. This evidence concerns the gene ERBB3 and bladder transitional cell carcinoma.